Form 4: Director Martha Shadan Acquires CVRx Equity

Director Martha Shadan was granted 8,720 shares of common stock and 11,182 stock options in CVRx, Inc.

Summary

• Director Martha Shadan received an equity grant consisting of 8,720 shares of common stock.
• The director also received 11,182 stock options with an exercise price of $5.43 per share.
• The securities vest on the earlier of June 1, 2027, or the date of the 2027 annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• None noted.

Risks

• Future value of equity and options is dependent on the market performance of CVRx common stock.

Future Outlook

The securities are subject to a vesting schedule tied to the 2027 annual meeting or the one-year anniversary of the grant.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice to ensure long-term alignment with shareholder value in the medical device sector.

Comparison to Industry Standards

• The grant of restricted stock and options is consistent with standard compensation packages for board members in mid-cap healthcare companies.

Stakeholder Impact

• Minimal impact on shareholders; reflects standard director compensation practices.

Next Steps

• Vesting of securities on June 1, 2027.

Key Dates

Keywords

CVRx, Insider Trading, Form 4, Equity Compensation, Director Compensation